This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Becton Dickinson (BDX) Down 3.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test
by Zacks Equity Research
BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.
Top Stock Reports for Disney, Adobe & NextEra
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Adobe (ADBE), and NextEra Energy (NEE).
The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co
4 Dental Stocks to Watch on Likely Industry Turnaround
by Zacks Equity Research
The dental equipment market seems ready to grow as it continues to recover from the COVID-19 pandemic slump, making it prudent to look at names like Henry Schein (HSIC) and McKesson (MCK)
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
All You Need to Know About Becton Dickinson (BDX) Rating Upgrade to Buy
by Zacks Equity Research
Becton Dickinson (BDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Align (ALGN) Extends Invisalign G8 Availability Worldwide
by Zacks Equity Research
Align's (ALGN) latest evolution in biomechanics is set to improve treatment predictability for frequently treated case types.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q1
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 44.90% and 0.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in Pharmaceutical segment.
What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Becton, Dickinson's (BDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Becton, Dickinson and Company (BDX).
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
by Urmimala Biswas
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results
by Zacks Equity Research
BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests
Testing Space in Focus Again Thanks to New Wave of Coronavirus
by Urmimala Biswas
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.